Clinical trial NCT02085252: A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Official title: An Open-Label, Multicenter, Phase III Study to Assess the Impact of Transient Androgenic Deprivation With Enantone LP 11.25 Mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Prostate Cancer
Keywords: Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2014-03-12
Enrollment: 116
Sex: MALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess two treatment strategies (leuprorelin treatment and active surveillance without androgen deprivation) for indolent prostate cancer and to compare their therapeutic benefit for management of patients with low-risk, localized prostate cancer.

Detailed description: The drug being tested in this study is called leuprorelin. Leuprorelin is being tested to treat people who have prostate cancer. Study assessments will include adverse events, prostatic-specific antigen (PSA) levels, and prostate biopsies.

The study will enroll approximately 120 patients. Participants will be randomly assigned (by chance, like flipping a coin) to a treatment group that will receive leuprorelin 11.25 mg (as one injection) or to an untreated observation group. Patients in the leuprorelin group will also receive bicalutamide 50 mg, a non-steroidal antiandrogen, once daily for 15 days to prevent a flare-up.

This multi-center trial will be conducted in France. The overall time to participate in this study is 12 months. After the screening visit, participants will make 6 visits to the clinic.

Eligibility criteria: Inclusion Criteria:

1. Is an out-patient 50 to 80 years old.
2. Has read, understood, signed and dated the informed consent.
3. Has indolent prostate cancer defined by:

   * Clinical Stage T1c or T2a.
   * Biopsy cores of which at least 12 reveal the presence of positive cores and the absence of cores with tumor length \> 3 mm.
   * Absence of Grade 4 cells (Gleason \<7).
   * Prostate specific antigen (PSA) levels \<10 ng/ml.
4. Has a life expectancy \> 5 years.
5. Has accepted the principle of active surveillance.
6. Is willing to participate in the study for a minimum of fifteen months.

Exclusion Criteria:

1. Has prior androgen deprivation including a 5-alpha reductase inhibitor (finasteride or dutasteride) within the last 6 months.
2. Has psychological failure related to prostate cancer therapy.
3. Has any active disorder likely to affect the conduct of the study or the patient's prognosis during the study.
4. Has a mental deficiency or any other reason that may hinder the understanding or strict application of the protocol.
5. Is under judicial protection, tutorship or curatorship.
6. Is unlikely to attend control visits.
7. Is currently enrolled in an investigational study or has participated in another investigational study within the last 3 months.
8. Has an allergy or hypersensitivity to any components of leuprorelin (Enantone LP) 11.25 mg or Casodex® 50 mg.
9. Has a medical history of severely impaired hepatic function linked to bicalutamide or a pathological cause.
10. Has testosterone level \< 0.5 ng/ml.

Primary outcomes:
measure: Number of Participants With Negative Biopsies at Month 12
timeFrame: Month 12
Secondary outcomes:
measure: Number of Participants With Gleason Score ≥ 7
timeFrame: Month 12
measure: Change From Baseline in the International Prostate Symptom Score (I-PSS) Total Symptom (S) Score
timeFrame: Baseline and Months 3, 6, 9 and 12
measure: Prostatic Volume as a Measure of Tumor Radiologic Progression Using Dynamic Magnetic Resonance Imaging (MRI)
timeFrame: Baseline and Month 12
measure: Highest Diameter of the Lesion as a Measure of Tumor Radiologic Progression Using Dynamic MRI
timeFrame: Baseline and Month 12
measure: Change From Baseline in Prostate-specific Antigen (PSA) Levels
timeFrame: Baseline and Months 3, 6, 9 and 12
measure: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score
timeFrame: Baseline and Months 3, 6, 9 and 12
measure: Change From Baseline in the International Index of Erectile Function (IIEF-5) Questionnaire Score
timeFrame: Baseline and Months 3, 6, 9 and 12
Other outcomes:
Locations:
city: Paris
country: France
facility: Tenon Hospital Paris France
city: Paris
country: France
facility: Ouzid, Paris La Défense,
Study officials:
affiliation: Takeda
name: Medical Director Clinical Science
role: STUDY_DIRECTOR
References: